136 related articles for article (PubMed ID: 16302793)
1. Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
Lund BW; Piu F; Gauthier NK; Eeg A; Currier E; Sherbukhin V; Brann MR; Hacksell U; Olsson R
J Med Chem; 2005 Dec; 48(24):7517-9. PubMed ID: 16302793
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
Imanishi M; Tomishima Y; Itou S; Hamashima H; Nakajima Y; Washizuka K; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
J Med Chem; 2008 Mar; 51(6):1925-44. PubMed ID: 18307290
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.
Nakajima Y; Imanishi M; Itou S; Hamashima H; Tomishima Y; Washizuka K; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Hattori K
Bioorg Med Chem Lett; 2008 Sep; 18(18):5037-40. PubMed ID: 18752946
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
Lund BW; Knapp AE; Piu F; Gauthier NK; Begtrup M; Hacksell U; Olsson R
J Med Chem; 2009 Mar; 52(6):1540-5. PubMed ID: 19239230
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
Klaholz BP; Mitschler A; Moras D
J Mol Biol; 2000 Sep; 302(1):155-70. PubMed ID: 10964567
[TBL] [Abstract][Full Text] [Related]
6. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
Baxter A; Cooper A; Kinchin E; Moakes K; Unitt J; Wallace A
Bioorg Med Chem Lett; 2006 Feb; 16(4):960-3. PubMed ID: 16297626
[TBL] [Abstract][Full Text] [Related]
7. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
[TBL] [Abstract][Full Text] [Related]
8. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor.
Alvarez S; Germain P; Alvarez R; Rodríguez-Barrios F; Gronemeyer H; de Lera AR
Int J Biochem Cell Biol; 2007; 39(7-8):1406-15. PubMed ID: 17433757
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new chemical leads for selective EP1 receptor antagonists.
Naganawa A; Saito T; Nagao Y; Egashira H; Iwahashi M; Kambe T; Koketsu M; Yamamoto H; Kobayashi M; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M
Bioorg Med Chem; 2006 Aug; 14(16):5562-77. PubMed ID: 16697646
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.
Cole DC; Stock JR; Lennox WJ; Bernotas RC; Ellingboe JW; Boikess S; Coupet J; Smith DL; Leung L; Zhang GM; Feng X; Kelly MF; Galante R; Huang P; Dawson LA; Marquis K; Rosenzweig-Lipson S; Beyer CE; Schechter LE
J Med Chem; 2007 Nov; 50(23):5535-8. PubMed ID: 17948978
[TBL] [Abstract][Full Text] [Related]
11. Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.
Pinard E; Alberati D; Borroni E; Fischer H; Hainzl D; Jolidon S; Moreau JL; Narquizian R; Nettekoven M; Norcross RD; Stalder H; Thomas AW
Bioorg Med Chem Lett; 2008 Sep; 18(18):5134-9. PubMed ID: 18752953
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
13. Structure-based optimization of benzoic acids as inhibitors of protein tyrosine phosphatase 1B and low molecular weight protein tyrosine phosphatase.
Maccari R; Ottanà R; Ciurleo R; Paoli P; Manao G; Camici G; Laggner C; Langer T
ChemMedChem; 2009 Jun; 4(6):957-62. PubMed ID: 19288492
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of thiazolo[3,2-a]pyrimidinone derivatives as general inhibitors of Bcl-2 family proteins.
Zhou B; Li X; Li Y; Xu Y; Zhang Z; Zhou M; Zhang X; Liu Z; Zhou J; Cao C; Yu B; Wang R
ChemMedChem; 2011 May; 6(5):904-21. PubMed ID: 21520420
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
Imanishi M; Nakajima Y; Tomishima Y; Hamashima H; Washizuka K; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
J Med Chem; 2008 Aug; 51(15):4804-22. PubMed ID: 18651730
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
Imanishi M; Itou S; Washizuka K; Hamashima H; Nakajima Y; Araki T; Tomishima Y; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
J Med Chem; 2008 Jul; 51(13):4002-20. PubMed ID: 18553954
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
[TBL] [Abstract][Full Text] [Related]
18. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
[TBL] [Abstract][Full Text] [Related]
19. Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1.
Noeske T; Trifanova D; Kauss V; Renner S; Parsons CG; Schneider G; Weil T
Bioorg Med Chem; 2009 Aug; 17(15):5708-15. PubMed ID: 19574055
[TBL] [Abstract][Full Text] [Related]
20. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
